Cite
HARVARD Citation
Paul, C. et al. (n.d.). Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). British journal of dermatology. pp. 1387-1399. [Online].